COMPOSITE MATERIALS FOR HARD TISSUE REPLACEMENT

用于硬组织置换的复合材料

• 批准号: 6209587
• 负责人: Silvia D Luebben
• 金额: $ 10万
• 依托单位: TDA RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-01 至 2001-08-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6209587
• 关键词: biodegradable product; biomaterial development /preparation; biomechanics; bone disorder; bone prosthesis; composite resins; hydroxyapatites; medical implant science; orthopedics; polymers

Bone defects caused by trauma, disease or congenital deficiency have traditionally been restored with graft procedures using endogenous bone, exogenous bone, or synthetic substitutes, including metals, ceramics, and polymers, as replacement materials. Although these methods have been used successfully for decades, all of them present drawbacks. During the last few years much research has been devoted to the development of bone substitutes that eventually degrade to allow re-growth of the natural bone. These efforts have led to the development of new biomaterials and a better understanding of the bone-forming process. In light of this new knowledge, TDA Research, Inc. (TDA) plans to develop a new inorganic-organic composite that can be used as a bone substitute to repair large and irregular bony defects. TDA's composite bone substitute will be used as a paste or putty at the time of the surgical procedure and can be shaped and processed in vivo. The cured material will have excellent mechanical properties and become porous after implantation. Porosity is crucial for obtaining osteoconductivity. Degradation products from TDA's biodegradable bone substitute will be non-toxic. The composite will be designed to retain strength as the degradation proceeds. PROPOSED COMMERCIAL APPLICATIONS: TDA's bone substitute will be used in the biomaterial industry of hard tissue replacement. Currently the biomaterial industry spends $2.3 billion on bone replacement materials (Suchanek 1998).

传统上，使用内源性骨骼，外源骨或合成替代物（包括金属，陶瓷和聚合物）作为替代材料，通过移植手术恢复了由创伤，疾病或先天性缺乏症引起的骨缺损作为替代材料。 尽管这些方法已成功使用了数十年，但所有这些方法都存在缺点。 在过去的几年中，许多研究都致力于骨替代品的发展，这些骨骼替代品最终降解以允许自然骨的重新生长。 这些努力导致了新的生物材料的发展，并更好地理解了骨形成过程。 鉴于这一新知识，TDA Research，Inc。（TDA）计划开发一种新的无机有机复合材料，该复合材料可用作修复大且不规则的骨缺陷的骨骼替代品。 TDA的复合骨替代物将在外科手术时用作糊状或腻子，可以在体内形成和处理。固化材料将具有出色的机械性能，并在植入后变为多孔。 孔隙率对于获得骨导率至关重要。 TDA可生物降解的骨骼替代品的降解产物将无毒。 该复合材料将在降解进行时保持强度。拟议的商业应用：TDA的骨骼替代品将用于硬组织替代的生物材料工业。 目前，生物材料行业在骨骼替代材料上花费了23亿美元（Suchanek 1998）。